340B Orphan Drug Rule: Stakeholders Are Parsing ACA Statute – Should Some Indications Be Cheaper Than Others?

Health care institutions that benefit from the recent expansion of the 340B program are applauding the HHS Health Resources and Services Administration’s interpretation of an orphan drugs provision that allows more products to be available at a discount. But some others question whether it fits with the plain language of the statute.